Although Pfizer has seen better revenue growth in recent years, AbbVie is more profitable.

Pfizer just got an approval for a drug to treat ulcerative colitis. AbbVie is still trying to consolidate its control over that market. Pfizer doesn't need a total victory to make things harder ...

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has also been expanding its offerings into solid tumors. Its ...

The stock's fall snapped a three-day winning streak.

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune ...

Five months after acquiring Biohaven, Pfizer has scored FDA approval for one of the drugs gained in the purchase, migraine nasal spray Zavzpret.

AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces ...

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.